                               SEQUENCE LISTING

<110> BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
 
<120> COMBINATION THERAPY FOR CANCER

<130> 167688.010802/PCT

<140> PCT/US2018/030488
<141> 2018-05-01

<150> 62/518,493
<151> 2017-06-12

<150> 62/500,456
<151> 2017-05-02

<160> 26    

<170> PatentIn version 3.5

<210> 1
<211> 7
<212> PRT
<213> Unknown

<220>
<223> Description of Unknown: Angiotensin-(1-7) peptide

<400> 1
Asp Arg Val Tyr Ile His Pro 
1               5           


<210> 2
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 2
Asp Arg Val Ser Ile His Cys 
1               5           


<210> 3

<400> 3
000


<210> 4
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Any amino acid or absent 

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Arg, Lys, Ala, Cit (citrulline), Orn (ornithine), acetylated 
      Ser, Sar, D-Arg or D-Lys 

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Val, Ala, Leu, Nle (norleucine), Ile, Gly, Lys, Pro, 
      HydroxyPro (hydroxyproline), Aib (2-aminoisobutyric acid), 
      Acpc (1-aminocyclopentane carboxylic acid) or Tyr 

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Tyr, Tyr(PO3), Thr, Ser, homoSer (homoserine), azaTyr 
      (aza-alpha1-homo-L-tyrosine) or Ala 

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Ile, Ala, Leu, norLeu, Val or Gly 

<220>
<221> MOD_RES
<222> (6)..(6)
<223> His, Arg or 6-NH2-Phe (6-aminophenylalaine)

<220>
<221> MOD_RES
<222> (7)..(7)
<223> Cys, Pro or Ala 

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 4
Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5           


<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (3)..(3)
<223> Nle

<400> 5
Asp Arg Xaa Tyr Ile His Pro 
1               5           


<210> 6
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 6
Asp Arg Val Ser Ile His Cys 
1               5           


<210> 7

<400> 7
000


<210> 8

<400> 8
000


<210> 9

<400> 9
000


<210> 10

<400> 10
000


<210> 11

<400> 11
000


<210> 12

<400> 12
000


<210> 13

<400> 13
000


<210> 14

<400> 14
000


<210> 15

<400> 15
000


<210> 16

<400> 16
000


<210> 17

<400> 17
000


<210> 18

<400> 18
000


<210> 19

<400> 19
000


<210> 20

<400> 20
000


<210> 21

<400> 21
000


<210> 22
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MISC_FEATURE
<222> (4)..(7)
<223> Linkage between residues 

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 22
Asp Arg Val Ser Ile His Cys 
1               5           


<210> 23
<211> 9
<212> PRT
<213> Unknown

<220>
<223> Description of Unknown: Angiotensin-(1-9) peptide

<400> 23
Asp Arg Val Tyr Ile His Pro Phe His 
1               5                   


<210> 24
<211> 7
<212> PRT
<213> Unknown

<220>
<223> Description of Unknown: Alamandine peptide

<400> 24
Ala Arg Val Tyr Ile His Pro 
1               5           


<210> 25
<211> 7
<212> PRT
<213> Unknown

<220>
<223> Description of Unknown: Angiotensin-(1-7) peptide

<400> 25
Asp Arg Val Ser Ile His Pro 
1               5           


<210> 26
<211> 12
<212> PRT
<213> Unknown

<220>
<223> Description of Unknown: Angiotensin peptide 

<400> 26
Asp Arg Val Tyr Ile His Pro Phe His Leu Val Ile 
1               5                   10          


